Telomir Pharmaceuticals, Inc. Files Form 8-K: What Investors Need to Know

Overview

Telomir Pharmaceuticals, Inc. (“Telomir” or “the Company”), a Florida-incorporated company in the pharmaceutical preparations sector, has filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) on April 30, 2026. The report covers events as of April 24, 2026.

Key Highlights

• Form Type: 8-K (Current Report)
• Date of Report: April 24, 2026
• Company Name: Telomir Pharmaceuticals, Inc.
• Trading Symbol: TELO
• Exchange: The Nasdaq Stock Market LLC
• Business Address: 100 SE 2nd St, Suite 2000 #1009, Miami, FL 33131
• Phone Number: (786) 396-6723
• Central Index Key (CIK): 0001971532
• Emerging Growth Company Status: Yes (the Company qualifies as an emerging growth company under SEC rules)
• Extended Transition Period for New Accounting Standards: The Company has not elected to use the extended transition period for complying with any new or revised financial accounting standards.
• Securities Registered: Common Stock, no par value
• Price Sensitive Filing Provisions: No written communications, soliciting material, or pre-commencement tender offers disclosed in this filing.
• Signatory: Erez Aminov signed the 8-K on behalf of the Company as of April 30, 2026.

Shareholder-Relevant Information

• Emerging Growth Company Status: Telomir is classified as an emerging growth company, which means it can take advantage of certain reduced disclosure and reporting requirements compared to larger public companies. This classification can affect the Company’s financial reporting and compliance costs, potentially benefiting shareholders through operational flexibility.
• Nasdaq Listing: The Company’s common stock continues to be listed on Nasdaq under the symbol TELO. Nasdaq listing supports liquidity and visibility for shareholders.
• No New Material Events Disclosed: This Form 8-K does not report any material corporate events, acquisitions, leadership changes, or other developments that would typically be considered price sensitive or likely to impact the share value directly.
• No Soliciting Material or Written Communications: There are no disclosures of written communications under Rule 425, nor any soliciting material under Rule 14a-12, or pre-commencement tender offers. This means no new M&A activity, capital raising, or other significant corporate actions are being disclosed at this time.
• Corporate Information Verified: The filing reaffirms the company’s business address, phone number, and SEC identifiers, ensuring all public records are up-to-date.

Conclusion for Investors

Price Sensitivity:
Based on this Form 8-K filing, there are no new material events, transactions, or announcements that would be expected to move Telomir Pharmaceuticals’ stock price in the short term. The filing is primarily administrative and confirms compliance with SEC reporting requirements, Nasdaq listing, and the Company’s emerging growth company status.

What to Watch:
Investors should continue to monitor Telomir Pharmaceuticals, Inc. for future filings or announcements that could impact financial performance, operations, or share value, as this filing does not introduce new, price-sensitive events.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The information is based solely on the referenced SEC filing and does not include any additional company disclosures or market analysis.

View Telomir Pharmaceuticals, Inc. Historical chart here